ArticleCardiology journal2025
Differences in coronary microcirculation measurements during regadenoson vs. adenosine - induced hyperemia.
Article in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the similarity of microcirculation assessment outcomes performed with regadenoson and adenosine. The aim of the current study was to compare coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) assessment using adenosine and regadenoson, and to evaluate predictors regarding the size of differences.
methods44 patients were enrolled and diagnosed between 2021 and 2023. Fractional flow reserve (FFR), CFR and IMR were measured twice in the circumflex (Cx) (n = 8) or left anterior descending (LAD) (n = 36) artery: once with continuous infusion of adenosine (Adenocor 140 µg/kg/min) and 10 minutes later with regadenoson (Rapiscan 400 µg i.v.).
resultsAveraged results were quantified with adenosine and regadenoson for FFR (0.81 [0.75 ÷ 0.89] vs. 0.80 [0.73 ÷ 0.88]), CFR (3.84 [1.67 ÷ 4.08] vs. 3.97 [1.78 ÷ 4.32]) and IMR (20.01 [11 ÷ 24.5] vs. 20.25 [10.75 ÷ 23]), respectively. None of the differences were statistically significant. Among the significant (p < 0.05) predictors of greater ΔCFR, the following can be noted: prior percutaneous transluminal angioplasty/carotid artery stenting (β = 2.35), oral anticoagulant usage (β = 0.89), and prior stroke/transient ischaemic attack (TIA) (β = 1.09), with the latter being also confirmed for greater ΔIMR (β = 8.89). Moreover, patients with New York Heart Association (NYHA) class II/III, as compared to those with NYHA class I, were more likely to have greater ΔIMR (β = 11.89).
conclusionsRegadenoson may be a feasible alternative to adenosine in coronary microcirculation assessment, as it produces similar outcomes. Selected factors were found to be predictors of greater differences in IMR, CFR and FFR values according to the agent used for coronary hyperemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.